Gerresheimer AG
OTC:GRRMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gerresheimer AG
OTC:GRRMY
|
DE |
|
E
|
Endeavour Mining PLC
DUS:6E2
|
UK |
|
E
|
Eurazeo SE
DUS:EUQ
|
FR |
|
Ivanhoe Mines Ltd
TSX:IVN
|
CA |
|
P
|
Palfinger AG
OTC:PLFRF
|
AT |
|
G
|
Goodbridge Capital Corp
XTSX:GODB.P
|
CA |
Gerresheimer AG
Gerresheimer makes glass and plastic packaging that protects medicines and other sensitive products. It also makes drug delivery devices such as insulin pens, inhalers, syringes, and other components that help patients store, measure, and take medicines safely. In simple terms, it sells the containers and delivery tools that pharmaceutical and healthcare companies need to get products to patients. Its main customers are drug makers, biotech companies, medical device companies, and some cosmetics and specialty consumer brands. Gerresheimer earns money by designing, manufacturing, and selling these packaging and delivery products, often as long-term supply relationships with customers that need reliable quality and strict regulatory compliance. Because many of its products are tied to regulated medicines, customers care a lot about precision, cleanliness, and consistency. What makes Gerresheimer different is that it sits at the point where materials science meets healthcare. It is not a drug company and not a finished-device brand; it is a supplier that helps other companies package and administer their products safely. That gives it an important role in the healthcare supply chain, especially for products that need sterile, high-quality, and highly controlled packaging.
Gerresheimer makes glass and plastic packaging that protects medicines and other sensitive products. It also makes drug delivery devices such as insulin pens, inhalers, syringes, and other components that help patients store, measure, and take medicines safely. In simple terms, it sells the containers and delivery tools that pharmaceutical and healthcare companies need to get products to patients.
Its main customers are drug makers, biotech companies, medical device companies, and some cosmetics and specialty consumer brands. Gerresheimer earns money by designing, manufacturing, and selling these packaging and delivery products, often as long-term supply relationships with customers that need reliable quality and strict regulatory compliance. Because many of its products are tied to regulated medicines, customers care a lot about precision, cleanliness, and consistency.
What makes Gerresheimer different is that it sits at the point where materials science meets healthcare. It is not a drug company and not a finished-device brand; it is a supplier that helps other companies package and administer their products safely. That gives it an important role in the healthcare supply chain, especially for products that need sterile, high-quality, and highly controlled packaging.
Guidance Cut: Management revised 2025 guidance downward, now expecting organic revenue to decline 2–4% and EBITDA margin at 18.5–19%, with adjusted EPS to fall by a mid-double-digit percent.
Q3 Miss: Q3 organic revenues fell 1.2% year-on-year, and adjusted EBITDA declined 9.4%, both below company expectations.
Market Weakness: Persistent softness in cosmetics and oral liquids markets weighed on performance, with no significant market share loss to competitors.
Bormioli Pharma Impact: The acquisition boosted reported revenue and EBITDA but organic growth remains negative; ramp-up of assets slower than expected.
Cash Focus: Positive free cash flow of EUR 21 million in Q3, no one-offs, but management remains cautious and focused on cash and CapEx discipline.
Moulded Glass Plan: The company is preparing to carve out and sell the Moulded Glass business, with new leadership in place.
Transformation Initiatives: A comprehensive transformation program is being implemented, including cost reductions, operational improvements, and a new segmentation starting in 2026.
